Oslo, 17. February 2016. Serodus ASA (OAX:SER) announces its results for the fourth quarter 2015.

Highlights include:

SER150 Diabetic Nephropathy

  • Completed patient randomization to Cohort 1 In Ph2a study in patients with diabetic nephropathy
  • Status after Cohort 1: No serious side effects identified, no drop outs from the study
  • Plans for continued clinical development into Phase 2b are being made
  • Established a strong international scientific advisory board.

SER130 Acute Myocardial Infarction

  • A pharmacological study in relevant test model was initiated in November and will continue in Q2, 2016.
  • Established a strong international scientific advisory board.

SER100 Pulmonary hypertension

  • Pharmacological data demonstrates decrease in elevated pulmonary pressure
  • Application for Orphan Drug Designation will be prepared
  • Results from the study will be published in the coming quarters

SER140 Type 2 Diabetes

  • A pharmacological study in a experimental Type 2 Diabetic model is still ongoing.
  • Established a strong international scientific advisory board.

Business development highlights

  • Engaged Anthony Rosenberg, with a lifetime experience in Business Development and Licensing from Novartis as advisor

Quarterly report and presentation are attached.

For more information contact:

Tore Kvam

CFO, Serodus ASA

Mobile: +47 959 34 199

e-mail: tore.kvam@serodus.com

Serodus ASA is a drug development company listed on Oslo Stock Exchange, focusing on new therapeutic products for the treatment of cardiovascular and metabolic diseases with large unmet clinical needs. The company's business model is to seek partnering with international pharmaceutical companies after having demonstrated clinical effect in humans. For more information see www.serodus.com.

Serodus ASA issued this content on 17 February 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 17 February 2016 08:19:18 UTC

Original Document: http://www.serodus.com/News/2016/Q4-2015-Interim-results